{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:10:02Z","timestamp":1772107802874,"version":"3.50.1"},"reference-count":0,"publisher":"Knowledge E DMCC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJHOSCR"],"abstract":"<jats:p>Background: T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive diseases with dismal prognoses.\r\nMaterials and Methods: All adult patients with T-ALL and T-LBL who were candidates for the Hyper-CVAD chemotherapy protocol were included. We evaluated overall survival and progression-free survival in 46 new cases. The T-ALL and T-LBL\u2019s number of cases were 32 and 14, respectively.\r\nResults: Two- and 3-year OS were 41.8% (standard error (SE): 7%) and 27.8% (SE: 7%), respectively. Two- and 3-year PFS were 36.9% (SE: 7%) and 25.3% (SE: 7%), respectively. The only variable that had a significant relationship with the duration of PFS and OS was Allogenic SCT. Patients receiving Allogeneic SCT had longer survival time (2-year overall survival of 80% against 20%) (p\u02c20.001).\r\nConclusion: \u00a0These data support the concept that Hyper-CVAD is not an appropriate and adequate regimen. We need new targeted agents in the T-ALL and T-LBL induction regimen while considering Allogeneic SCT as a Consolidation.<\/jats:p>","DOI":"10.18502\/ijhoscr.v19i4.19981","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:58:38Z","timestamp":1760954318000},"source":"Crossref","is-referenced-by-count":0,"title":["Outcome of T-Lymphoblastic Leukemia-Lymphoma with Hyper C-VAD Regimen"],"prefix":"10.18502","author":[{"given":"Nasrin","family":"Namdari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elahe","family":"Ataei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatame","family":"Ghanbarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sezaneh","family":"Haghpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maral","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7770","published-online":{"date-parts":[[2025,10,20]]},"container-title":["International Journal of Hematology-Oncology and Stem Cell Research"],"original-title":[],"link":[{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/download\/19981\/18547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/download\/19981\/18547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:26:09Z","timestamp":1772105169000},"score":1,"resource":{"primary":{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/view\/19981"},"secondary":[{"URL":"https:\/\/ijhoscr.tums.ac.ir\/index.php\/ijhoscr\/article\/view\/2453","label":"UNIVERSITY"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":0,"URL":"https:\/\/doi.org\/10.18502\/ijhoscr.v19i4.19981","relation":{},"ISSN":["2008-2207"],"issn-type":[{"value":"2008-2207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]}}}